All In Biotech

Drug Trial Radar · NCT06495931

Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human

A Single-center, Single-arm, Open, Fixed-sequence, Self-controlled Study of the Pharmacokinetic Effects of HRS-1780, Henagliflozin, Metformin, and HRS-7535 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jul 15, 2024

Primary completion

Aug 13, 2024

Study completion Aug 13, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study was designed as a single-center, single-arm, open, fixed-sequence, self-controlled trial in healthy subjects.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • HRS-1780 tabletsDrug

    HRS-1780 tablets, three times

  • HR20033 tabletsDrug

    HR20033 tablets, nine times

  • HRS-7535 tabletsDrug

    HRS-7535 tablets ,three times or nine times

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parameters:CmaxTime frame: 0 hour to 24 hours after the last dosing
  2. PK parameters:AUC0-tTime frame: 0 hour to 24 hours after the last dosing
  3. PK parameters:AUC0-∞Time frame: 0 hour to 24 hours after the last dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xuanwu Hospital ,Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.